MS Novel treatment of multiple sclerosis MS

摘要

The invention relates to the use of an R-enantiomer of a compound according to formula (I) for the treatment of multiple sclerosis (MS), or a nitro-variant of said compound, and a pharmaceutically acceptable salt of said compound, (R-flubiprofen): RTI ID = 0.0 In this formula, R ₁ or R ₂ is a group selected from H, -CH ₃ , -CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , and -CH ₂ CH ₂ CH ₂ CH ₃ or taken together with the other to form a cyclopropyl ring , A cyclobutyl ring, a cyclopentyl ring, or a cyclohexyl ring, and R ₃ is -COOH, -COOR ₆ , -CONH ₂ , -CONHR ₆ , -CONR ₆ R ₇ , -CONHSO ₂ R ₆ , - COO- (CH ₂ ) ₃ -CH ₂ OH, -COO- (CH ₂ ) ₄ -ONO ₂ , -COO-PhOCH ₃ -C ₂ H ₂ -COO- (CH ₂ ) ₄ -ONO ₂ , tetrazolyl, and is a group selected from -COOH biological equivalents, R ₄ or R ₅ is -Cl, -F, -Br, -I, -CF 3, -OCF 3, -SCF 3, -OCH 3, -OCH 2 CH 3, -CN, -CH = CH _2, a group selected from -CH ₂ OH, and -NO _2, R ₆ or R ₇ is _{-CH 3, -CH 2 CH 3,} -CH 2 CH 2 CH 3, and - CH ₂ CH ₂ CH ₂ CH ₃ , and m or n is an integer selected from 0, 1, 2, and 3.